HemostOD Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $2.53M

  • Investors
  • 10

HemostOD General Information

Description

Developer of ex vivo platelets intended to provide a donor-free source of universal platelets. The company generates high quantities of engineered platelets using its bioengineering platform, enabling patients with thrombocytopenia and supporting applications in tissue-targeted cargo delivery, regenerative medicine, and therapeutic stem cell culture.

Contact Information

Website
www.hemostod.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • EPFL Innovation Park Batiment M
  • Rue des Jordils, 1A
  • 1025 Saint-Sulpice
  • Switzerland
Primary Industry
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • EPFL Innovation Park Batiment M
  • Rue des Jordils, 1A
  • 1025 Saint-Sulpice
  • Switzerland

HemostOD Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HemostOD Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Grant 03-Feb-2026 $2.53M Completed Pre-Clinical Trials
8. Seed Round 03-Oct-2025 Completed Pre-Clinical Trials
7. Accelerator/Incubator 04-Nov-2023 Completed Pre-Clinical Trials
6. Accelerator/Incubator Completed Pre-Clinical Trials
5. Debt - General 03-May-2022 Completed Pre-Clinical Trials
4. Seed Round 02-May-2021 Completed Pre-Clinical Trials
3. Accelerator/Incubator Completed Pre-Clinical Trials
2. Grant 17-Nov-2020 $11K Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view HemostOD’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

HemostOD Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of ex vivo platelets intended to provide a donor-free source of universal platelets. The company generates hig
Biotechnology
Saint-Sulpice, Switzerland
9 As of 2025

Kyoto, Japan
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

HemostOD Competitors (1)

One of HemostOD’s competitors is Megakaryon, a Formerly VC-backed company based in Kyoto, Japan.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Megakaryon Formerly VC-backed Kyoto, Japan
You’re viewing 1 of 1 competitors. Get the full list »

HemostOD Patents

  • 23

    Total Documents Applications and Grants

  • Total Patents Families

  • 7

    Granted

  • 10

    Pending

  • Expiring in next 12 mo

HemostOD Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4678735-A1 Method of high-density cell culture and cells thereof Pending 08-Jul-2024
WO-2026012999-A1 Method of high-density cell culture and cells thereof Pending 08-Jul-2024
EP-4506448-A1 Generation of immortalized progenitor megakaryocytes from human hematopoietic stem cells for large scale platelet production into microfluidics device Pending 09-Aug-2023
WO-2025031669-A1 Method of producing immortalized progenitor megakaryocytes from adult human hematopoietic stem and progenitor cells for in vitro large-scale functional platelet generation Inactive 09-Aug-2023
EP-4461301-A1 A method for producing engineered platelets Inactive 07-May-2023 C12N5/0644
To view HemostOD’s complete patent history, request access »

HemostOD Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HemostOD Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Innosuisse Government
Lichtsteiner Foundation Limited Partner Minority
Orenok Holdings Corporation Minority
Polytechnique Ventures Venture Capital Minority
EIT Health Accelerator/Incubator
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

HemostOD FAQs

  • When was HemostOD founded?

    HemostOD was founded in 2020.

  • Where is HemostOD headquartered?

    HemostOD is headquartered in Saint-Sulpice, Switzerland.

  • What is the size of HemostOD?

    HemostOD has 9 total employees.

  • What industry is HemostOD in?

    HemostOD’s primary industry is Biotechnology.

  • Is HemostOD a private or public company?

    HemostOD is a Private company.

  • What is HemostOD’s current revenue?

    The current revenue for HemostOD is .

  • How much funding has HemostOD raised over time?

    HemostOD has raised $7.39M.

  • Who are HemostOD’s investors?

    Innosuisse, Lichtsteiner Foundation, Orenok Holdings, Polytechnique Ventures, and EIT Health are 5 of 10 investors who have invested in HemostOD.

  • Who are HemostOD’s competitors?

    Megakaryon is a competitor of HemostOD.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process